We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Amgen’s Appeal Fails in Repatha Patent Case
Amgen has failed to convince the U.S. Court of Appeals for the Federal Circuit that Sanofi and Regeneron Pharmaceuticals should be made to pay for infringing its patents on its cholesterol drug Repatha (evolocumab).